C Reactive Protein Test Market Overview
The C Reactive Protein Test Market is witnessing steady growth as the prevalence of chronic and inflammatory diseases increases and healthcare providers place greater emphasis on early diagnosis and preventive healthcare. The market was valued at USD 2 billion in 2024 and is expected to grow from USD 2.1 billion in 2025 to USD 3.5 billion by 2035, expanding at a CAGR of 5.4% during the forecast period.
North America is projected to dominate the global market, supported by high healthcare expenditure, advanced laboratory infrastructure, increasing health awareness, and the adoption of advanced diagnostic technologies. Asia-Pacific is expected to witness the fastest growth as healthcare infrastructure improves and awareness of inflammation biomarkers increases. Among test types, High-Sensitivity C-Reactive Protein Testing represents an important segment, valued at USD 800 million in 2024 and projected to reach USD 1.3 billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=650019
Key Companies in the C Reactive Protein Test Market
DiaSorin
Ortho Clinical Diagnostics
Becton Dickinson
Merck KGaA
Abbott Laboratories
Quidel Corporation
bioMérieux
ELITechGroup
Roche
Hologic
Siemens Healthineers
A. Menarini Diagnostics
Thermo Fisher Scientific
Fujifilm
Danaher Corporation
Randox Laboratories
The C Reactive Protein Test Market is being driven by the rising prevalence of chronic diseases, increasing demand for early diagnosis, growing awareness of inflammation biomarkers, and expanding clinical applications of CRP testing. Technological advances in high-sensitivity assays, point-of-care testing, and laboratory automation are improving the accuracy, accessibility, and efficiency of CRP testing.
The market is segmented by Test Type, Sample Type, Technology, End User, and Region. By Test Type, it includes High-Sensitivity C-Reactive Protein Test, Standard C-Reactive Protein Test, and Quantitative C-Reactive Protein Test. By Sample Type, the market covers Blood, Serum, and Plasma. Technologies include Immunoassays, Enzyme-Linked Immunosorbent Assay, and Lateral Flow Assays, while end users comprise Hospitals, Diagnostic Laboratories, and Research Institutes.
Significant opportunities exist through the development of point-of-care testing solutions, advanced high-sensitivity assays, personalized medicine applications, and next-generation laboratory technologies. Expansion into developing markets and the increasing adoption of home healthcare and telemedicine solutions can further broaden access to CRP testing.
Recent Developments and Market Trends:
DiaSorin announced in April 2025 the acquisition of a leading hs-CRP assay developer to strengthen its inflammatory biomarker portfolio and expand high-sensitivity CRP testing on its LIAISON platform.
Ortho Clinical Diagnostics and Roche announced a strategic partnership in September 2024 to co-develop and commercialize high-sensitivity CRP assays across their immunoassay platforms.
Fujifilm Wako Diagnostics launched a new high-sensitivity CRP assay on the LUMIPULSE platform in June 2024 to support faster inflammation assessment.
High-sensitivity CRP testing is gaining importance for inflammation assessment and cardiovascular risk evaluation.
Point-of-care CRP testing is gaining traction because it can provide rapid results in emergency and primary-care settings.
Home healthcare testing is emerging as consumers increasingly seek convenient and accessible health-monitoring solutions.
Advances in laboratory automation and diagnostic technologies are improving testing efficiency and analytical performance.
Growing awareness of the relationship between inflammation and chronic, autoimmune, and infectious diseases is supporting demand for CRP testing.
Asia-Pacific is expected to experience the fastest growth as healthcare infrastructure, diagnostic capabilities, and health awareness continue to improve.
Reasons to Buy the Report:
Understand the current market size and projected growth of the global C Reactive Protein Test Market.
Analyze key growth drivers including chronic disease prevalence, early diagnosis, preventive healthcare, and growing awareness of inflammation markers.
Evaluate opportunities across test types, sample types, technologies, end users, and regional markets.
Assess the competitive landscape and strategies of leading CRP testing companies.
Understand the impact of high-sensitivity assays, point-of-care testing, and laboratory automation on market development.
Identify opportunities associated with personalized medicine, home healthcare, and diagnostic expansion in developing markets.
Future Outlook:
The C Reactive Protein Test Market is expected to maintain steady growth through 2035 as demand for early diagnosis, preventive healthcare, and inflammation assessment continues to increase. North America is expected to remain the leading regional market, while Asia-Pacific offers significant expansion potential as healthcare infrastructure and diagnostic access improve. Continued innovation in high-sensitivity assays, point-of-care technologies, laboratory automation, home testing, and personalized medicine is expected to shape the market’s future. With the market projected to reach USD 3.5 billion by 2035 at a CAGR of 5.4%, opportunities remain strong for diagnostic companies developing accurate, accessible, and technologically advanced CRP testing solutions.
➤➤Explore Our Latest Related Reports:
